Medicines Australia Code of Conduct review – consultation open

3 April 2024: Medicines Australia invites all pharmaceutical companies operating in Australia and other stakeholders with an interest in the Medicines Australia Code of Conduct to participate in our 2024 Code Review.

The Medicines Australia Code of Conduct is regarded globally as the gold standard of industry self-regulation.

The first Code of Conduct was launched in 1960, and since then it has undergone regular revisions to reflect best practice and respond to changing practices in advertising and engagement with health professionals.

The Code of Conduct is reviewed approximately every five years in line with standard best practice. The last review was undertaken in 2019 resulting in a significant update, the principles-based Code Edition 19, that came into effect in March 2020.

The current review seeks input from members and non-member pharmaceutical companies as well as industry associations, peak healthcare professional organisations, patient groups, healthcare professionals, the Therapeutic Goods Administration and Australian Competition and Consumer Commission (ACCC) and other key stakeholders. 

A Consultation Paper outlining seven key topics and the process objectives, timeframe, and methodology, is available for all interested stakeholders to consider and has been developed to guide the review. Feedback outside the topics identified is also welcome.

Review feedback can be submitted via our online form or via email. The consultation period will close on Thursday 2 May 2024.

Any recommendations that result from the Review will be considered by Medicines Australia members at the Annual General Meeting in October 2024. 

The Consultation Paper and online form can be found on our website – www.medicinesaustralia.com.au/codereview2024 

__________________________________________________________________________

Media enquiries to Kate McKeown, Senior Manager Communications and Media – kate.mckeown@medicinesaustralia.com.au or 0408 775 288.